The U.S. Food and Drug Administration (FDA) approved a subcutaneous version of Sanofi’s multiple myeloma drug, Sarclisa (isatuximab-irfc). This new formulation utilizes a wearable, on-body injector for administration.
The delivery method significantly reduces administration time compared to traditional intravenous infusions. This approval enhances the drug's competitive profile against other treatments in the multiple myeloma market.
Sanofi designed the under-the-skin injection to decrease the treatment burden on both patients and healthcare facilities. The regulatory milestone supports the company’s broader strategy to strengthen its oncology pipeline.